BiotechTube
Scope Biosciences

Scope Biosciences

Wageningen, Netherlands· Est.
scopebio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Scope Biosciences is an early-stage diagnostics company leveraging CRISPR-Cas technology to create rapid, field-deployable molecular tests for agricultural pathogens. Its flagship platform, scopeDx®, offers PCR-level sensitivity and single-nucleotide specificity in a simple, one-hour workflow usable by non-experts on crude samples. The company has launched a portfolio of assays for key crops like tomato, pepper, and cucumber and is positioned to address the critical need for early disease detection to prevent yield loss and reduce unnecessary chemical inputs in agriculture.

Diagnostics

Technology Platform

CRISPR-Cas-based molecular diagnostic platform (scopeDx®) for rapid, on-site detection of plant pathogens with PCR-level sensitivity and single-nucleotide specificity.

Opportunities

The global push for sustainable agriculture and reduced pesticide use creates strong demand for precise diagnostic tools.
The platform's flexibility allows for rapid development of custom assays for emerging threats or niche markets, creating a service-based revenue stream.
Expansion into adjacent verticals like seed testing, soil health, or veterinary diagnostics represents long-term growth potential.

Risk Factors

Market adoption risk in a conservative agricultural sector reliant on traditional practices.
Potential competition from larger ag-tech or diagnostic companies entering the CRISPR diagnostics space.
Execution risk associated with scaling manufacturing, distribution, and sales operations from an R&D-focused startup.

Competitive Landscape

Scope competes with traditional send-away lab services (slow), antibody-based lateral flow strips (less sensitive/specific), and lab-based PCR equipment (complex, expensive). Its primary differentiation is combining PCR-level accuracy with point-of-need simplicity. Other startups may be exploring similar CRISPR-dx applications, but Scope appears to have an early-mover advantage in agricultural focus and a robust initial product portfolio.

More companies in CRISPR / Gene Editing →More companies in Netherlands →